DEINOVELife genius delivered

1

PROFILELife genius delivered

2

Disruptive innovationTO ANSWER HEALTH AND ENVIRONMENTAL CHALLENGES

BioactivesActive ingredients of natural origin for cosmetics and nutrition

Next-generation anti-infectives to fight antimicrobial resistance

Antibiotics

Innovative molecules from rare and extremophilic microorganisms

Lead generation platform

Life genius delivered

3

FOUNDED IN

2006BASED IN MONTPELLIER 62 HIGHLY-

SKILLED STAFF310 PATENTS WORLDWIDE

LISTED IN PARIS

SINCE 20101,500 M2

LAB FACILITIES

A cutting-edge biotechnology platform

Biodiversity BioInformatics Fermentation Extraction & purification

Genetic engineering Analytics Screening

INNOVATIVE, ECO-FRIENDLY, ACTIVE MOLECULES FROM CONCEPTION TO PRODUCTION

4

Exclusive 6,000+

rare strains collection Understanding the metabolic pathways

Developing efficient production processes

Isolating and formulating molecules for their final use

Guiding and optimizing the production of molecules

Controlling production process and product characteristics

Functional activities testing

BIOACTIFS

Phyt-N-Resist®Phytoene (colorless carotenoid) Proprietary asset

Hebelys®With Greentech

Innovative CarotenoidProprietary asset

Oléos 1 & 2With Oléos-Hallstar

COLOR2BWith Avril

DNV 3837Active againstClostridium difficile

AGIR

Preclinical

Severe gastro-intestinal infections

Phase I Phase II Phase III

Discovery platform for novel antibiotic structures

Programs under development

Anti-aging cosmetic ingredient

Anti-aging cosmetic ingredient

Cosmetic active ingredients

Natural feed additives

Research DevelopmentIndustrial scale-up

Market

Cosmetic active ingredient

Bioactives

Antibiotics

5

ANTIBIOTICSNext-generation anti-infectives to fight antimicrobial resistance

6

The challenge of AntiMicrobial Resistance (AMR)A MAJOR THREAT FOR HUMANITY

Source: Revue on antimicrobial resistance

A global health challenge

FIND NOVEL ANTIBIOTIC STRUCTURES TO FIGHT RESISTANT PATHOGENSIS AN URGENT NEED

«Antimicrobial resistance is a slow-motion tsunami

that must be managed with the utmost urgency.»

Dr. Margaret Chan, Director-General of WHO, Sept.2016

7

700,000DEATHS / YEARTODAY

10 millionsDEATHS / YEARIN 2050

A risk for the world economy$100

TRILLIONS

LOSS OF ECONOMIC OUTPUT WORTH BY 2050

Healthcare costs

Challenging the ability to continue performing daily medical procedures

(transplantations, chemotherapy...)

Platform dedicated to the exploration of rare microorganismsand identification of novel antibiotic structures

Discovery Platform

8

AGIR (=“ACT”) : ANTIBIOTICS AGAINST RESISTANT INFECTIOUS GERMS

AGIR Antibiotiquescontre les GermesInfectieux Résistants

A FIRST NCE DISCOVEREDDNB101/102Published in Nature Chemical Biology

Two patent applications

€14.6 MFrench Government funding

RESEACH COLLABORATIONS Access to new strains

BIODIVERSITYProprietary library of 6,000 extremophilic strains

Development of the automated

discovery platform

Lead optimization and process development

Production of molecules with optimal

performances

Bacteria Antibiotics

DNV3837 antibiotic candidate ready to enter Phase II

9

TARGETING SEVERE CLOSTRIDIUM DIFFICILE INFECTIONS (CDI)

FREQUENCY

RECURRENCE

MORTALITYDesignated as an URGENT threat by the CDC

(American Centers for Disease Control and Prevention)

CLOSTRIDIUM DIFFICILEAntibiotic-resistant spore-forming

bacterium that colonizes the intestine

Sources:U.S. Centers for Disease Control: Antibiotic Resistance Threats in the United States, 2013. Desai et al., BMC Infectious Diseases 2016; 16. Decision Resources: Treatment trends, C. diff Infections (US) 2012; (EU) 2013

CDI are currently two to four times more common than Hospital Acquired Diseases caused by methicillin-resistant Staphylococcus aureus (MRSA) which have been a leading public health concern for many years

~20% re-admission within 30 days

Steadily increasing, as a result of the development of highly virulent strains

40% of patients suffer from a severe form

35-50% : mortality rate of patients with severe CDI with complications (megacolon, perforation)

CLOSTRIDIUM DIFFICILE INFECTIONS

Clostridium difficile Infections (CDI)A FAST-EXPANDING DISEASE, A REAL THERAPEUTIC NEED

10

INCIDENCE OF CDI (THOUSANDS OF CASES) +27%

364411

481

662

2012 2021

EUROPE USA

845

1,073

GROWING ISSUE

INCREASED AWARENESS

SIGNIFICANT IMPACT

AGEING POPULATIONIncreasing number of people in long term care (LTC) facilities

Increasing number of beds per hospital/LTC facility

UNDER-ESTIMATED DIAGNOSISAbsence of clinical suspicion

Suboptimal diagnosis methods

Unreported cases due to the embarrassing nature of illness

HUMAN AND ECONOMIC COSTUSA: 44,500 deaths / year Europe: 3,700 deaths / year Economic Impact: $10 B / year

Sources: Decision Resources: Treatment Trends C. diff. Infections (EU) 2013. Davies et al. LID 2014. LESSA ET AL., 2015. MORPHOCHEM.

DNV3837A POSSIBLE EFFECTIVE THERAPEUTIC OPTION

11

FAST TRACK STATUS& QIDP DESIGNATION granted by FDA

READY TO ENTERPHASE IIScheduled for mid-2019Multicentric trial

3 CONCLUSIVE PHASE I TRIALS• ≈ 100 healthy volunteers• Very targeted activity• Acceptable tolerance profile

1ST LINE TREATMENTof severe Clostridium difficile infections

Only 2 oral drugs approved for treatment of CDI: vancomycin & fidaxomicin

Ineffective in severe cases (facing colitis, intestinal paralysis....)

No approved IV treatment available, off-label metronidazole does not reduce mortality

TREATMENT BY INTRAVENOUS INJECTION

Easier to administer in severe casesMore efficient

DNV3837

12

A NOVEL ANTIBIOTIC CLASS

PRESERVES THE GUT MICROBIOTE• Reduces viable counts of Gram-positive

anaerobic bacteria (C.difficile)• Does not affect Gram-negative microflora

Bacterial concentration in stoolC. diff. vs Gram-negative flora

single subjects

log10

CFU/

g fec

es

Pre-dose Last day of Day 7 of infusion (Day 5) post-exposure

ClostridiaeBacteroides

DNV3837• New class of small molecule:

quinolonyl-oxazolidinone • Powerful inhibitor of ribosomal translation

and DNA gyrase• Interact with topoisomerase IV • Down-regulates two T-RNA synthetases

N

FO

OH

O

NO

F

NO

NH

O

OOPO

OOH Na+

DNV3837

13

IV TREATMENT EFFECTIVE AGAINST GASTRO-INTESTINAL INFECTIONS

Vancomycin Metronidazole Fidaxomicin DNV3837

mg/

L

0.0

0.5

1.0

1.5

2.0

Antibiotic activity against C. difficile(MIC90, range ; 114 clinical isolates)

0.5

1

0.125 0.064

Pre-dose

mg

/ kg

fece

s

50

100

150

200

High fecal concentration of the drug after IV administration

117 ± 92

250

Day 2 Last day of infusion

0

171 ± 43

SUPERIOR EFFICACY• Superior to reference treatments

against 114 different isolates of C. difficile• Including the highly virulent NAP1 strain

TARGETED ACTIVITY• High drug concentration in stool (site of

infection)• Fecal concentration exceeds by far MIC90

(minimum concentration to inhibit 90% growth of pathogenic strains)

DNV3837CLINICAL DEVELOPMENT PROGRAM

14

MULTICENTRIC INTERNATIONAL PHASE II MID-2019

SCHEDULED FOR

10-12 MONTHSDuration of study

~40 PATIENTS2 cohorts : moderate and severe

15 CLINICAL CENTRESGermany (5)USA (10)

DEINOVE CHOSE MEDPACE AS A CROSupport for the design and supervision of the clinical trialData collection and analysisInteractions with the FDA

BIOACTIVESActive ingredients of natural origin for cosmetics and nutrition

15

The 1st 100% DEINOVE-made activeAN INNOVATIVE AND DIFFERENTIATED ANTI-AGING INGREDIENT

16

SCIENTIFICALLY PROVEN• in vitro / ex vivo testing

•Proven clinical benefits

PREMIUM •100% pure

molecule

•Highly concentrated

MULTI-APPLICATION•Antioxidant ++

•Skin renewal

ACTIVE INGREDIENTInnovative Carotenoid

Phyt-N-ResistTHE FIRST PURE PHYTOENE

ECO-FRIENDLY•Bioproduction•From natural sugars•Reproducible process

Deinococcus: bacteria hyper-resistant to extreme conditions: heat, drought, radiation…

Deinobased

PATENTEDTECHNOLOGY

ENHANCED SKIN REGENERATION AND HEALINGTARGETED ANTIOXIDANT PROTECTION

VISIBLE ANTI-AGING BENEFITS

Phyt-N-Resist®PROVEN CLINICAL BENEFITS

17

FIRMNESSX2

ELASTICITYX3 as of 28 days

-17% WRINKLES DEPTH

RADIANCE

D0 D28 D56

PROMOTES COMPLETE SKIN REGENERATION after 14 days vs 20 days under natural conditionsIn vivo DHA Test

– 80%LIPID OXIDATIONvs untreated explantsEx vivo tests ACCELERATES

SKIN REPAIRIn vitro tests

An outsourced and diversified distribution strategyWORLDWIDE DISTRIBUTION AGREEMENTS

Marketing agreementReGeN-oPhyt®

North America and Asia Distribution agreementPhyt-N-Resist®

EMEA

1 Source L’Oréal

18

37%Asia-Pacific

18%Western Europe

11%Latin America

6%Eastern Europe

25%North America

WORLDWIDE SALES OF COSMETIC PRODUCTS

3%Africa, ME

€200 B WORLD COSMETIC MARKET1

+ 4 to 5% PER YEAR

37% SKINCARE

Marketing agreementReGeN-oPhyt®

North America and Asia

HEBELYS, DEVELOPED WITH GREENTECH

Anti-aging active for mature skin

An expanding portfolio of assetsFULLY-OWNED AND CO-DEVELOPED

19

A 2ND 100% DEINOVE-MADE ACTIVE IN DEVELOPMENTa dermocosmetic indication showing strong growth

Major player in the production and distribution of biotechnologically derived ingredientsSells a hundred active ingredients derived from biodiversity to cosmetics manufacturers in over 30 countries

2018LAUNCHED IN

TWO INGREDIENTS IN DEVELOPMENT100% natural cosmetic actives with OLÉOS

Part of the American group HALLSTARProprietary Oleo-Eco-Extraction technology Has already developed twenty or so active ingredients marketed to cosmetics brands in France and abroad

2019/2020SCHEDULED FOR

2019LAUNCH SCHEDULED

FOR

A catalogue of qualified active extractsMULTIPLE OPPORTUNITIES FOR COLLABORATION

Aloh’age®

Antioxidant HealingTahiti

Arenactive®

AntioxidantHealingAnti-inflammatoryMediterranean beach

Tropicalis®

AntioxidantLa Réunion island

Luccamine®

AntioxidantHealingAnti-inflammatory Corsica

Luminaris®

Antioxidant WhiteningCanary Islands

DOZENS OF RARE STRAINS…

20

ANTIOXIDANTAnti-aging, anti-UV…

HEALINGAnti-aging, damaged skin…

LIPID STORAGEPlumping, moisturizing…

ANTI-INFLAMMATORYSensitive / irritated skin

Post-operative skin care…

LIPOLYSISSlimming, Anti-cellulite…

WHITENINGLightening/brightening, Anti-blemish…

… WITH CONFIRMED COSMETIC PROPERTIES

Example of a bacterial extract availableANTIOXIDANT AND HEALING PROPERTIES

21

ClaimsFEATURES• Sample source: Taravao, Tahiti

• Type of sample: vegetal (lichen)

• Isolation temperature: 45°C

Aloh’age INNOVATIVE AND NATURAL ACTIVE EXTRACT

ANTIOXIDANT AND HEALING PROPERTIES

EXTREMOPHILIC MICROORGANISM

DOSE-EFFECTACTIVITY

ANTI-AGING

UV PROTECTION

DAMAGED SKIN

POST-OPERATION TREATMENT

Healing testin vitro

Oxidation testin vitro

COLOR2BNATURAL FEED ADDITIVES

SCREENING OF THE STRAIN LIBRARY

SELECTION AND EVALUATION OF STRAINS OF POTENTIAL INTEREST

CHARACTERIZATION OF THE MOLECULES PRODUCED, OPTIMIZATION OF PRODUCTION CONDITIONS

DEMONSTRATED EFFECTIVENESS IMPROVING OPTIMAL DOSAGE

NEXT STEPSIndustrialization of productionRegulatory pathwayLicense agreementLaunch of new animal nutrition products

OBJECTIVE: TO LAUNCH A NEW RANGE OF NATURAL PRODUCTSAvril, a key player in the French oil and protein sectorDevelopment of a natural alternative to petroleum-based ingredientsProject co-financed by both partners

22

Business model BioactivesREACHING THE COMMERCIALIZATION STAGE

23

• COMPOUNDS DEVELOPED IN-HOUSE• TOLL MANUFACTURING• DISTRIBUTION VIA INGREDIENTS

SUPPLIERS / SALES PER KG

DIRECT MARKETING

• R&D COLLABORATIONS• TECHNOLOGY LICENSES• ROYALTIES ON SALES

INDUSTRIAL PARTNERSHIPS

GENERATE

SHORT-TERM

INCOME

CORPORATE PROFILEManagement and financial data

24

The DEINOVE stock

25

EURONEXT GROWTH PARIS

MARKET CAPITALIZATION

LISTED IN PARIS

SINCE 2010ISIN

FR001087905615.8mTRADABLE SHARES

€ 23m MARKET CAP

125,000 SHARES / DAY

€1.48SHARE PRICE AS AT 28.02.19

0

10

20

30

40

50

60

janv-18 avr-18 juil-18 oct-18 janv-19

11.28%Funds managed by Truffle Capital

0.54%Management

0.25%Scientific founders(M. Radman, Université P. Descartes)

80.83%Free float

7.11%Funds managed

by TVM Capital

BREAKDOWN OF SHARE CAPITAL as at 31 December 2018 (non diluted basis)

BROKER TARGET DATE

Arrowhead €4.6 26.09.18

Edison €4.0 04.04.18

Midcap partners €4.3 15.05.18

Invest Securities €5.2 01.10.18

Financial data – FY 2018

26Confidential

• Vs -€7.3m in 2017

• Operating revenues +€0,8m (vs €0.2m in 2017)

• Operating costs (€11.2m), 76% of which are R&D expenses

NET RESULT: -€8.7m

• Vs +€4.9m as at 31.12.17

• Cash-out: operating expenses (€10.4m) ; investments (€1.9m)

• Cash-in: capital increase (€8.0m) ; equity line (€0.7m) ; public grants (€2.6m)

• Post-closing Cash-in: R&D tax credit (€2.5m) ; AGIR - 1st instalment (€1.5m)

CASH POSITION 31.12.18: +€3.9m

Provides the resources required until Q2 2020, using the equity line

MANAGEMENTAN EXPERIENCED TEAM

Coralie MartinHead of Communication, Marketing and Investor Relations

Johane Rinaldi Head of HR

Emmanuel PetiotCEO

Julien CosteDirector of Finance & Administration

Georges GaudriaultScientific Director

Marie BézengerDirector of Operations

Sébastien Enault Head of Business Development

27

A high-level board of directorsPROVEN EXPERIENCE IN HEALTH AND BIOTECH

28

Philippe POULETTYFounder of Truffle Capital Founder of SangStat acquired by Genzyme for 600M$

Charles WOLER, ChairmanFormerly Chairman and CEO of Roche FranceChairman of Genfit & GSK Europe

Vincent JARLIERHead of Bacteriology Department, Pitié-Salpétrière HospitalFounder & President of ONERBA (National observatory for epidemiology of bacterial resistance to antibiotics)

Hervé BRAILLYCo-founder & Chairman of Supervisory Board at Innate Pharma

Yannick PLÉTANChief medical officer, Head of clinical R&D and medical affairs at Acticor Biotech

Anne ABRIAT-HEMMENDINGERFounder of The Smell & Taste LabFormerly Product development and marketing for L’Oréal and Coty

Investment highlights

29

DISRUPTIVEA pioneer biotechnology company producing innovative and naturally-sourced active molecules based on a unique collection of rare microorganisms and cutting-edge technological platform

LATE-STAGE CLINICAL DEVELOPMENTThe DNV3837 program: launch of Phase II of a first-in-class antibiotic targeting an unmet medical need for severe Clostridium difficile infections

DIVERSIFIEDA diversified portfolio of innovative

compounds for applications in three markets with high added value:

Cosmetics, Health and Nutrition

COMMERCIAL STAGEDe-risked technology

Two products already on the market

SUCCESSFUL STRATEGIC MOVE

30

CONTACTS

MONTPELLIER, FRANCECAP SIGMA - ZAC Euromédecine II1682 rue de la Valsière 34790 GRABELS

www.deinove.com

Emmanuel PETIOTCEOPh: + 33 6 13 80 25 30emmanuel.petiot@deinove.com

Coralie MARTINCommunication, Marketing and Investor relations managerTel.: + 33 4 48 19 01 60coralie.martin@deinove.com

APPENDICES

31

Business model AntibioticsA SECTOR OF ACTIVITY ELIGIBLE FOR NON-DILUTIVE FUNDING TO SUPPORT RESEARCH

• PUBLIC RESEARCH SUPPORT PROGRAMMES

• ACCELERATED APPROVAL PROCEDURES AND EXTENSION OF INDUSTRIAL PROTECTION PERIODS

• MANY PRIVATE INITIATIVES

STATE / INSTITUTIONAL SUPPORT

• R&D COLLABORATIONS

• LICENSING AGREEMENTS / RIGHTS GRANTING ON MOLECULES

INDUSTRIAL PARTNERSHIPS

32